(PubMed) Carr AC, Pullar JM, Bozonet SM, Vissers MC
Pharmacokinetics (Coskun et al., Cell Metabolism 2022) Phase 1 PK data established the ~6-day half-life and once-weekly dosing rationale
Stable CHO-SNAP-GLP-1R and MIN6B1-SNAP-GLP-1R cells were generated by transfecting pSNAP-GLP-1R (Cisbio) into wild-type CHO-K1 (ECACC) or MIN6B1, G418 (1 mg ml 1 ) selection, and single-cell sorting by fluorescence-activated cell sorting (FACS) following SNAP-Surface-488 (New England Biolabs) labeling
Measure your levels today and save $250
Last week, Novo Nordisk announced that Eli Lilly's Zepbound 15 mg outperformed its lead next-generation obesity treatment candidate, CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg) in the 84-week, phase III REDEFINE 4 study
It stimulates insulin secretion, reduces glucagon release, and slows gastric emptying, helping you feel fuller longer